Strategic Partnerships SIGA's collaboration history with academic and defense-related entities (Vanderbilt University, JPEO-CBRND) indicates openness to licensing, co-development, and contract-based programs. Target opportunities include monoclonal antibody licenses, translational collaborations, and international promotion alliances to expand the reach of TPOXX and related therapeutics.

Expanded Indications Active development of post-exposure prophylaxis for oral TPOXX suggests reimbursement and adoption potential in military, first-responder, and healthcare worker markets. Propose pilots and regulatory-supported programs to broaden PEP labeling and clinical use across high-risk populations.

Public Funding Levers With existing development contracts and government-backed programs, there are opportunities to align sales with defense and public health funding cycles. Position solutions as augmenting national security and outbreak readiness to secure multi-year, funded orders.

Global Market Access SIGA operates internationally through promotion amendments and licenses; identify regions with unmet infectious disease needs and favorable regulatory environments to propose distribution partnerships, regional manufacturing or co-promotion agreements for TPOXX and future antivirals.

Strategic Growth Signals Revenue scale and ongoing collaborations imply readiness for scalable commercial engagements. Propose enterprise-wide support bundles, including regulatory consulting, supply chain stability, and training programs for healthcare providers to accelerate adoption and expand market share.